Addex to Present at the H.C. Wainwright Global Life Sciences Conference
March 04 2021 - 1:00AM
Geneva, Switzerland, March 4,
2021 - Addex Therapeutics Ltd
(SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
company pioneering allosteric modulation-based drug discovery and
development, announced today that Tim Dyer, Chief Executive
Officer, will present at the H.C. Wainwright Global Life
Sciences Conference (March 9-10, 2021).
In his presentation, which is scheduled for
Tuesday, March 9, 2021 at 07:00 ET, Mr Dyer will provide a
corporate update and discuss recent developments at Addex.
The video presentation will be available for viewing
on-demand by registered participants via this link from the time of
the presentation and subsequently on the Events page the
Company’s website (www.addextherapeutics.com). The video replay
will be archived for 90 days following the event.
Management will be available for virtual
one-on-one meetings throughout the conference. For more information
or to schedule a one-on-one meeting with management, please contact
your conference representative or James@HaydenIR.com.
About Addex Therapeutics:Addex
Therapeutics is a clinical-stage pharmaceutical company focused on
the development and commercialization of an emerging class of novel
orally available small molecule drugs known as allosteric
modulators for neurological disorders. Allosteric modulators offer
several potential advantages over conventional non-allosteric
molecules and may offer an improved therapeutic approach to
conventional "orthosteric" small molecule or biological drugs.
Adder’s allosteric modulator drug discovery platform targets
receptors and other proteins that are recognized as essential for
therapeutic intervention. adder’s lead drug candidate, dipraglurant
(mGlu5 negative allosteric modulator or NAM), is poised to start a
pivotal registration clinical trial for Parkinson’s disease
levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also
investigating dipraglurant's therapeutic use in blepharospasm (a
type of dystonia), for which a clinical trial is expected to be
initiated in H1 2021. Addex's third clinical program, ADX71149
(mGlu2 positive allosteric modulator or PAM), developed in
collaboration with Janssen Pharmaceuticals, Inc, is scheduled to
enter a phase 2a proof of concept clinical study for the treatment
of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed
to Indivior PLC who are focused on development for the treatment of
addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7
NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4
PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative
disorders. Addex is listed on the SIX Swiss Exchange and the NASDAQ
Capital Market and trades under the ticker symbol "ADXN".
Press Contacts:
Tim DyerChief
Executive Officer+41 22 884 15 55PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 (0) 20 7318
2955msinclair@halsin.com |
James Carbonara
Hayden IR (646)-755-7412 james@haydenir.com |
Forward Looking Statements:This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including in respect of the anticipated initiation of
clinical trials. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release, are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in Addex Therapeutics’ Annual
Report on Form 20-F for the year ended December 31, 2019, as filed
with the SEC on April 27, 2020, the prospectus related to the
global offering and other filings that Addex Therapeutics may make
with the SEC in the future. Any forward-looking statements
contained in this press release represent Addex Therapeutics’ views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date. Addex
Therapeutics explicitly disclaims any obligation to update any
forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Addex Therapeutics (NASDAQ:ADXN)
Historical Stock Chart
From Apr 2023 to Apr 2024